TITLE

Gabapentin and nortriptyline combined was better than either drug alone for relief of neuropathic pain

AUTHOR(S)
Hughes, James
PUB. DATE
March 2010
SOURCE
ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a medical research related to effectiveness of combined gabapentin and nortriptyline in comparison to alone drug for neuropathic pain. In a clinical trial around 56 patients with neuropathy is being observed and treated with combined drugs. It concluded that gabapentin and nortriptyline combined was better than either drug alone.
ACCESSION #
48839867

 

Related Articles

  • Change of purpose.  // Nature;5/20/2010, Vol. 465 Issue 7296, p267 

    The article focuses on the repurposing of existing drugs. It mentions that when a drug was no longer protected by patents, it was difficult for a pharmaceutical company to reimburse the investment to test the drug. It states that several solutions on the issue have been proposed such as the...

  • Evaluation of antidepressant activity of tramadol in mice. Tayal, Vandana; Kalra, Bhupinder Singh; Chawla, Shalini // Indian Journal of Pharmacology;Jun2008, Vol. 40 Issue 3, p129 

    Objective: To evaluate antidepressant like effect of tramadol in mice. Materials and Methods: Tramadol was administered at three different doses (10,20 and 40 mg/kg, i.p) once daily for 7 days to Swiss albino mice of either sex. The immobility period of control and drug treated mice were...

  • From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain. Barrot, Michel; Yalcin, Ipek; Choucair-Jaafar, Nada; Benbouzid, Malika; Freund-Mercier, Marie-José // Recent Patents on CNS Drug Discovery;Nov2009, Vol. 4 Issue 3, p182 

    The market for pain treatment is a major segment of nervous system pathologies. Despite this dynamism, the management of some pain conditions remains a clinical challenge. Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory system. It is generally a...

  • Nortriptyline, gabapentin, or both for neuropathic pain.  // Clinical Oncology Alert;Jan2010 Supplement, p1 

    The article discusses research on the efficacy of nortriptyline and gabapentin alone and in combination in treating neuropathic pain (NPN). It references a study by I. Gilron et al published in a 2009 issue of "Lancet." The study demonstrated that the combination of the two agents have achieved...

  • Nortriptyline, gabapentin, or both for neuropathic pain.  // Clinical Cardiology Alert;Jan2010 Supplement, Vol. 15 Issue 1, p1 

    The article discusses research on the efficacy of nortriptyline and gabapentin alone and in combination in treating neuropathic pain (NPN). It references a study by I. Gilron et al published in a 2009 issue of "Lancet." The study demonstrated that the combination of the two agents have achieved...

  • Suicidal ideation higher in men taking nortriptyline.  // Reactions Weekly;11/21/2009, Issue 1279, p4 

    The article discusses a clinical trial which assessed suicidal ideation during treatment of escitalopram and nortriptyline for depression. Findings suggest that suicidal-ideation rates associated with antidepressant therapy tends to be higher in male but not female patients taking nortriptyline,...

  • State of the Controlled Clinical Trial Enterprise in the United States. Krall, R. L. // Clinical Pharmacology & Therapeutics;Feb2011, Vol. 89 Issue 2, p225 

    We undertook a survey of the current capability in the United States to conduct controlled clinical trials. The intention was to use the results as a foundation for understanding how to create a controlled clinical trial capability sufficient to meet future needs of US health care. For this...

  • The need to consider the wider agenda in systematic reviews and meta-analyses. Ioannidis, John P. A.; Karassa, Fotini B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/9/2010, Vol. 341 Issue 7776, p762 

    This article focuses on the need for systematic reviewers to consider the whole drug research programme for the interventions under study. Two reasons behind the research problem include the testing of the drug for several indications and stopping the first trials early. It argues that the drug...

  • R&D Update.  // PharmaWatch: CNS;Oct2006, Vol. 5 Issue 10, p17 

    The article offers pharmaceutical research-related news briefs in the U.S. A positive performance reflected for BioDelivery Sciences International Inc.'s analgesic product, Bema LA. The clinical trial for LidoPAIN patch of EpiCept Corp. obtained negative results for its pain reliever effects. A...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics